This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
In one approach, they mark targetedproteins with “destroy me” tags that work with smallmolecules known as molecular glues to prompt the cell’s own protein-clearing machinery to gobble up the proteins. PACE allows researchers to rapidly evolve new proteins that have useful features.
TPD is a rapidly evolving therapeutic modality to degrade a disease-causing proteins, thereby eliminating their function specifically. 1 TPD is expected to challenge undruggable proteins, which are highly difficult to target by conventional smallmolecules. How does TPD work?
Shortly after finishing my studies, I landed my first job in industry working on cell biology research for several disease indications. At the time, research and leadership roles in biotech/pharma industry were predominately held by men and there were not as many opportunities for career development and mentorship from women leaders.
Sygnature Discovery identifies potent SHP2 degrader compounds using its proprietary targetedproteindegrader platform, CHARMED, in collaboration with Japanese specialty chemical company, UBE Corporation. Its staff of over 1,000, which includes 900 scientists, partners with global pharma, biotech and NFP organisations.
The research community pressed on, turning to novel compounds that were substantially more potent than those used in the first generation. Groundbreaking strategies like proteolysis-targeting chimeric molecules (PROTACs) are also being explored. Dual cytotoxic payload ADCs could address the inherent heterogeneity in tumours.
Promising future Molecular glues offer exciting opportunities for targetedproteindegradation and new ways to reach some of the estimated 85% of undruggable targets in the proteome. Conventional drug development has often focused on finding smallmolecules that fit the active site of a protein.
Program focused on identifying smallmolecules that target a GPCR for degradation as potential therapeutic agents for gastrointestinal disorders.
Unique combination of novel technologies to enhance GPCR drug discovery and expand capabilities into wider drug target universe.
a leading biotechnology company developing smallmolecule therapeutics based on its proprietary uSMITE platform of targetedproteindegradation technology, today announced that the company’s internal program to develop selective degraders that target key proteins within the TRK family has been published by the Journal of Medicinal Chemistry. “In
ICR and Cancer Research UK spinout closes Series B financing.
Monte Rosa Therapeutics has raised $96m in Series B financing to support further develop of its pipeline of small-moleculeproteindegraders. Earlier this year, Monte Rosa announced that it had raised an initial £32.5m
We are happy to support their scientific efforts as they tackle complex research challenges that potentially address critical unmet medical needs for patients. Our Degradomer® class of targetedproteindegraders expands on the Trilomer® concept, allowing highly specific degradation of disease-causing proteins.
Lacking active sites entirely, transcription factors are instead largely regulated by post-translational modification, which in turn impacts changes in conformation, behavior, and interaction with other proteins.
We organize all of the trending information in your field so you don't have to. Join 15,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content